Related Experiment Video
Updated: Jul 16, 2026

Measuring Caspase Activity Using a Fluorometric Assay or Flow Cytometry
Published on: March 24, 2023
A role for caspase-1 in heart failure
Sabine Merkle1, Stefan Frantz, Michael P Schön
1Rudolf Virchow Center, Deutsche Forschungsgemeinschaft-Research Center for Experimental Biomedicine, Wuerzburg, Germany.
Insights
Caspase-1, a proapoptotic protein, drives heart failure by directly inducing cardiomyocyte apoptosis. Deleting caspase-1 protects against heart failure and ischemia/reperfusion injury, revealing its critical role in cardiac disease progression.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Cell Death Pathways
Background:
- Cardiomyocyte apoptosis contributes to heart failure progression.
- The role of proinflammatory caspases, like caspase-1, in cardiac function is not well understood.
- Previous research suggested a proinflammatory role for caspase-1.
Purpose of the Study:
- To investigate the role of caspase-1 in the heart, particularly in the context of heart failure.
- To determine if caspase-1 has a proapoptotic or proinflammatory function in cardiomyocytes.
- To elucidate the therapeutic potential of targeting caspase-1 in cardiac diseases.
Main Methods:
- Gene array analysis and protein expression studies in murine and human heart failure models.
- Generation of transgenic mice with cardiomyocyte-specific caspase-1 overexpression.
- Utilizing genetically modified mice (caspase-1 deficient) in myocardial infarction and ischemia/reperfusion injury models.
- In vitro studies using primary rat cardiomyocytes.
Main Results:
- Caspase-1 expression is upregulated in murine and human heart failure.
- Overexpression of caspase-1 in cardiomyocytes induced apoptosis and heart failure without significant inflammation or IL-1beta/IL-18 production.
- Deletion of endogenous caspase-1 conferred protection against myocardial infarction and ischemia/reperfusion-induced injury.
- Caspase-1 mediates cardiomyocyte apoptosis via activation of caspases-3 and -9.
Conclusions:
- Caspase-1 plays a primary proapoptotic role in cardiomyocytes, distinct from its previously suggested proinflammatory function.
- Caspase-1-mediated cardiomyocyte apoptosis contributes significantly to the progression of heart failure.
- Targeting caspase-1 may offer a novel therapeutic strategy for heart failure and related cardiac conditions.
Abstract:
Apoptosis of cardiomyocytes is increased in heart failure and has been implicated in disease progression. The activation of "proapoptotic" caspases represents a key step in cardiomyocyte apoptosis. In contrast, the role of "proinflammatory" caspases (caspases 1, 4, 5, 11, 12) is unclear. Here, we study the cardiac function of caspase-1. Gene array analysis in a murine heart failure model showed upregulation of myocardial caspase-1. In addition, we found increased expression of caspase-1 protein in murine and human heart failure. Mice with cardiomyocyte-specific overexpression of caspase-1 developed heart failure in the absence of detectable formation of interleukin (IL)-1beta or IL-18 and inflammation. Transgenic caspase-1 induced primary cardiomyocyte apoptosis before structural and molecular signs of myocardial remodeling occurred. In contrast, deletion of endogenous caspase-1 was beneficial in the setting of myocardial infarction-induced heart failure. Furthermore, caspase-1-deficient mice were protected from ischemia/reperfusion-induced cardiomyocyte apoptosis. Studies in primary rat cardiomyocytes indicated that caspase-1 induces cardiomyocyte apoptosis primarily through activation of caspases-3 and -9. In contrast to previous findings, which imply a proinflammatory role of caspase-1, these data suggest a primary proapoptotic role for caspase-1 in cardiomyocytes. Our findings support a functional role for caspase-1-mediated myocardial apoptosis contributing to the progression of heart failure.
Related Concept Videos
Caspases
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology
Heart Failure I: Introduction
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy II: Dilated Cardiomyopathy

